ClinicalTrials.gg
Status unknownNCT00530569HER 2Updated Jan 28, 2013

Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy

An observational study in Breast Cancer, sponsored by Alberta Health services. Status unknown at 1 site in Canada. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-01-28.

Sponsored by Alberta Health services · Observational

How we know

The sponsor has not verified this record recently (last verified Jan 2012), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 907 studies in Breast Neoplasms with a site in Canada — 139 open to participants now, 257 under way, 81 of them phase 3. Breast Neoplasms · Canada.

Planned enrollment
88th of 110
60 · median 199
Started
2007
with 27 others
Observational
110 of 907
34 open now
Registered
187th of 907
by date

Among the 907 studies in Breast Neoplasms with a site in Canada, this one is the 88th largest by planned enrollment of the 110 observational ones that give a count, is one of 28 that started in 2007, is one of 110 observational ones, and was the 187th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

139 of the 907 studies in Breast Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

134 more — sign in →

All 139 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 907 studies in Breast Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

About 30% of breast cancers have higher than normal levels of a cellular marker called HER2. The amount of HER2 is often measured in breast tissue. A higher level of this marker usually indicates a more aggressive type of breast cancer. Cytokeratin is a second cellular marker found in breast cancer cells. Detection of Circulating cytokeratin in the blood could indicate the presence of cancer. The Pathology Department of the Tom Baker Cancer Center is doing this study to see if measuring the levels of circulating HER2 and cytokeratin, through blood testing has clinical significance for patients with breast cancer.

Read the detailed description
  • Single Variate analysis will be performed to correlate variables such as tumour size, grade, stage, ER status, PR status and biopsy HER2 status with soluble HER2 levels.
  • Soluble HER2 levels will be analyzed as both a continuous and categorized variable.
  • The analysis will attempt to discern the relationship between soluble HER2 levels, HER2 positive circulating epithelial cell level and treatment response.
  • This will provide evidence of the effect various treatments have on HER2 levels. HER2 levels both in patients treated with Herceptin and those on other treatment protocols, will be related to clinical disease measures such as time to progression, time to failure, duration of response and duration of survival.
  • An initial model of the relationship between these factors and soluble HER2 as a marker will be established from the data.
03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Herceptin Therapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Albertan women with breast cancer who will undergo Herceptin therapy as part of their treatment at some point during a one-year period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Albertan women with breast cancer who will undergo Herceptin therapy as part of their treatment at some point during a one-year period.

Exclusion criteria

Exclusion Criteria:

  • Greater than 80 years of age
  • Previous cancer diagnosis - (other than skin cancer)
05

Study design

Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Interventions

  • ProcedureBlood Test

    CBC and HER2 level at baseline, prior to each chemo and/or herceptin cycle, one month after chemo and/or herceptin completion, quarterly up to 12 months or a maximum of 20 blood draws.

06

Study locations

1 site
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 28, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00530569
Lead sponsor
Alberta Health services
First posted
Sep 17, 2007
Start date
Aug 2007
Last update
Jan 28, 2013

Study contacts

Bill Kangerloo, M.D.
principal investigator · Alberta Health services

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion